Abstract
There are no Food and Drug Administration (FDA)-approved medications for the medical management of frontotemporal dementia and its related disorders, so all management recommendations are necessarily off-label and borrowed from experience with Alzheimer's disease, psychiatric disease, and related medical illnesses. Six areas of pharmacotherapeutic consideration are prevention (primary and secondary), intellectual decline, behavioral disorders (such as depression, anxiety, and psychosis), sleep disorders, frequently associated disorders (including motor neuron disease), and abrupt decline. In addition to pharmacotherapy, important lifestyle issues confronting the clinician include driving cessation, securing any weapons maintained at home, assisted living, and caregiver burnout.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 489-498 |
| Number of pages | 10 |
| Journal | American Journal of Alzheimer's Disease and Other Dementias |
| Volume | 22 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 2008 |
Keywords
- Dementia and motor neuron disease
- Frontotemporal dementia
- Pharmacotherapy of dementia
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Psychology
- Geriatrics and Gerontology
- Psychiatry and Mental health